Matthew Lloyd Childers

This inventor holds 19 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 12 EPO patents, primarily in Inhibitor Compounds. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Lloyd Childers. Retrieved from https://idiyas.com/inventor/matthew-lloyd-childers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 9)

Average Co-Inventor Count = 12.3

ph-index = 4

Forward Citations = 41(Granted Patents)

Location History:

Newton Highlands, MA (US) (2013)
Boston, MA (US) (2019)
Medfield, MA (US) (2016 - 2023)

Company Filing History:

19 out of 2,405

Merck Sharp + Dohme Corp.

patents

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Arginase Inhibitors

Cyclic Di-Nucleotide Compounds

STING Agonists

Tricyclic Compounds

IDH Enzymes

IRAK4 Activity

Janus Kinase Inhibitors

Carboxamide Inhibitors

Cycloalkyl Nitrile

Cyanomethylpyrazole

Geminally Substituted

Pyrazolo Pyridones

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240867 - Arginase inhibitors and methods of use (2025-03-04),

2. 12215116 - Arginase inhibitors and methods of use (2025-02-04),

3. 11685761 - Cyclic di-nucleotide compounds as sting agonists (2023-06-27),

4. 11311528 - Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors (2022-04-26),

5. 10793557 - Sting agonist compounds (2020-10-06),

6. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),

7. 10759825 - Cyclic di-nucleotide compounds as STING agonists (2020-09-01),

8. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),

9. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

10. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

11. 10155765 - Carboxamide inhibitors of IRAK4 activity (2018-12-18),

12. 10086000 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2018-10-02),

13. 9969749 - Inhibitors of IRAK4 activity (2018-05-15),

14. 9957264 - Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors (2018-05-01),

15. 9932350 - Inhibitors of IRAK4 activity (2018-04-03),

Title: Matthew Lloyd Childers: A Pioneer in Arginase Inhibitors

Introduction: Matthew Lloyd Childers, located in Medfield, MA, is an accomplished inventor with a significant portfolio of 19 patents. His work primarily focuses on developing innovative compounds that target arginase-related diseases. Matthew's contributions to the field of medicinal chemistry are noteworthy, and his latest inventions showcase his dedication to improving healthcare.

Latest Patents: Among Matthew's latest patents are innovative compounds formulated as arginase inhibitors. These compounds, represented as Formula (I) in his patents, serve as vital therapeutic agents. They hold the promise of preventing and treating various diseases associated with arginase, demonstrating significant potential in the pharmaceutical industry.

Career Highlights: Matthew has built a remarkable career at Merck Sharp & Dohme Corporation, where he has applied his expertise in medicinal chemistry and pharmacology. His innovative approaches have led to advancements in the development of arginase inhibitors, solidifying his reputation as a leading inventor in his field.

Collaborations: Throughout his career, Matthew has collaborated with talented colleagues including Michael D. Altman and Jongwon Lim. These partnerships have enhanced his research and development initiatives, fostering an environment of creativity and innovation within the pharmaceutical sector.

Conclusion: Matthew Lloyd Childers exemplifies the spirit of innovation in the pharmaceutical industry. With his 19 patents and focus on arginase inhibitors, he continues to make significant strides towards understanding and treating arginase-related diseases. His dedication and collaboration with esteemed colleagues further underscore the importance of teamwork in driving technological advances in healthcare.

Profile summary based on public USPTO records.